Validation of Cognitive Screenings for the Hearing Impaired

Status Terminated

Clinical Trial Summary

There are currently no cognitive tests that have been validated as screening tools for people with dementia and comorbid hearing loss. This is particularly important given the high prevalence of hearing impairment in older adults presenting to memory services and the risk of misdiagnosis of dementia in this population as outlined above. Cognitive tests validated in hearing impaired populations will also be important as outcome tools for interventional research aiming to find out if treating hearing loss may reduce dementia risk in the longer term.

Clinical Trial Description

Hearing loss is very prevalent in older population. This leads to further problems such as communication problem, isolation from the community and depression. Moreover, hearing impairment may potentially affect the patients' cognitive function as demonstrated in the above mentioned published papers. Communication problems that arise from a hearing loss alone can also interfere with administration of cognitive test battery, as a previous study showed that re-administered of MMSE test with assistive listening device can immediately improve the test score among elderly (1). Therefore, special adaptation of the cognitive test battery to address the needs of hearing impaired older adult is necessary. This is to ensure that the test result reflects the exact cognitive state of the older adult with hearing impairment, not effected by hearing loss. Moreover, appropriate cut-off point scores for hearing impaired population should be identified for these new cognitive screening tools. This is to ensure appropriate referral for further diagnosis and prompt management for cognitive impairment/dementia among older adults with hearing loss. In addition, since hearing loss can potentially lead to deterioration in patients' cognitive function over time (2). Follow up assessments of cognitive function among older adults with hearing impairment can determine the rate of deterioration in retrospective trial(2). This prospective trial follow up of cognitive function among hearing loss participants may uncover additional risk factors associated with the deterioration. Better understanding of these risk factors can potentially lead to further intervention in order to delay decline in patients' cognitive function. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03648502
Study type	Interventional
Source	University College, London
Contact
Status	Terminated
Phase	N/A
Start date	November 9, 2018
Completion date	March 13, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05686486` - Gentle Gymnastics and Relationship Between Family Caregivers and Residents With Dementia in Nursing Homes	N/A
Terminated	`NCT05451693` - Outreach-ER: A Dementia Care Intervention Program
Recruiting	`NCT05820919` - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase	N/A
Enrolling by invitation	`NCT06040294` - Dementia and Disability Simulation for College Nursing Students' Senior Activity Facilitation Skills	N/A
Completed	`NCT05114187` - An Internet-Based Education Program for Care Partners of People Living With Dementia	N/A
Recruiting	`NCT06322121` - Vascular Aspects in Dementia: Part 2
Active, not recruiting	`NCT03676881` - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Completed	`NCT04426838` - Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad	N/A
Recruiting	`NCT03462485` - Pilot Study of the Effects of Playing Golf on People With Dementia	N/A
Active, not recruiting	`NCT03677284` - Managing Time With Dementia: Effects of Time Assistive Products in People With Dementia	N/A
Completed	`NCT03849937` - Changing Talk Online (CHATO) Study	N/A
Recruiting	`NCT06284213` - Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
Recruiting	`NCT05579236` - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed	`NCT05080777` - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems	N/A
Completed	`NCT04571697` - A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
Completed	`NCT03583879` - Using Gait Robotics to Improve Symptoms of Parkinson's Disease	N/A
Recruiting	`NCT06033066` - Financial Incentives and Recruitment to the APT Webstudy	N/A
Active, not recruiting	`NCT05204940` - Longitudinal Observational Biomarker Study
Recruiting	`NCT05684783` - Dementia Champions in Homecare
Completed	`NCT03147222` - Function Focused Care: Fracture Care at Home	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.